Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytotect CP Biotest for Prevention of Maternal-fetal CMV Transmission
NCT05170269Phase 3Terminated
- Sponsor
- Biotest AG
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- IgG Antibodies, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Megalotect in congenital cytomegalovirus infection (cCMV), sponsored by Biotest AG. Started Nov 2021; status: terminated.
02
Drugs
Megalotect
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on NCT05170269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170269.